A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.

Chatzidionysiou K, Turesson C, Teleman A, Knight A, Lindqvist E, Larsson P, Cöster L, Forslind K, van Vollenhoven R, Heimbürger M. RMD Open. 2016 Jan 14;2(1):e000133.